A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Phase 3
Completed
- Conditions
- Prostate Neoplasms
- Interventions
- Other: Androgen deprivation therapy (ADT)
- First Posted Date
- 2012-10-26
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1209
- Registration Number
- NCT01715285
A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2012-10-16
- Last Posted Date
- 2013-02-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 15
- Registration Number
- NCT01707316
A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16
Phase 1
Completed
- Conditions
- Healthy Volunteers and Asthma
- Interventions
- Drug: Placebo (asthmatic patients)Drug: CNTO 3157 (healthy participants)Drug: Placebo (healthy participants)Drug: CNTO 3157 (asthmatic patients)Other: HRV-16
- First Posted Date
- 2012-10-11
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT01704040
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma
Phase 1
Completed
- Conditions
- Tumor or Lymphoma
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 188
- Registration Number
- NCT01703481
A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy
Phase 3
Completed
- Conditions
- Prostate Neoplasms
- Interventions
- First Posted Date
- 2012-09-27
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 214
- Registration Number
- NCT01695135
Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2013-07-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 33
- Registration Number
- NCT01690286
A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2013-03-04
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT01689623
A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 139
- Registration Number
- NCT01689649
A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer
- First Posted Date
- 2012-09-17
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 82
- Registration Number
- NCT01685983
A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: PlaceboDrug: JNJ-38518168 (3 mg)Drug: JNJ-38518168 (10 mg)Drug: JNJ-38518168 (30 mg)
- First Posted Date
- 2012-09-06
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 272
- Registration Number
- NCT01679951
© Copyright 2025. All Rights Reserved by MedPath